Episode 1, Part 3 of PharmTech AI Pulse Check covers why INTerpath-001's AI isn't ChatGPT and names pharma manufacturing's biggest AI governance gaps.
News|Articles|January 1, 2016
- Pharmaceutical Technology-01-02-2016
- Volume 40
- Issue 1
Ultra High-Performance Liquid Chromatograph System
The Prominence-i LC-2030 LT is a new model of Shimadzu’s i-Series integrated high-performance liquid chromatograph and ultra high-performance liquid chromatograph systems.
The Prominence-i LC-2030 LT is a new model of Shimadzu’s i-Series integrated high-performance liquid chromatograph and ultra high-performance liquid chromatograph systems. The new system comes without a PDA and UV detector, allowing users to select a detector of their choice. The system provides a 14-second injection cycle time and 1536 continuous, unattended analyses using 4 x 384 well micro plates. The new model contains a color touch panel that supports control of the analysis, monitoring instrument status, and usage of the system and consumables. The panel also assists with maintenance and displays a chromatogram. The system contains auto-startup, auto system suitability test, quick-batch function, auto-shutdown, and auto-validation for system qualification. Instrument power can be turned off upon shutdown, saving more than 95% of standby electricity. Solvent and sample consumption can also be reduced to one-fifth of the usual amount without sacrificing data quality.
Articles in this issue
over 10 years ago
Parenteral Packaging: 2021over 10 years ago
Politics and Pricing Will Challenge Manufacturers in 2016over 10 years ago
Managing Market Expansion’s Effect on Proceduresover 10 years ago
Phase-Appropriate Formulation and Process Designover 10 years ago
Reducing the Documentation Burden in Process Validationover 10 years ago
Reducing the Environmental Impact of Manufacturingover 10 years ago
Cleaning Limits—Why the 10-ppm Criterion should be Abandonedover 10 years ago
Using Deterministic Container Closure Integrity Testingover 10 years ago
The Market Consolidates for Better Serviceover 10 years ago
Global Drug DirectionsRelated to this article
Michael Levy, senior vice president, Digital & Innovation, USP, explains the digital supply chain in a preview of his upcoming CPHI Milan panel presentation, The Next Phase of Pharma Supply Chains.
FDA approves tavapadon, first D1/D5 agonist, validating AbbVie's $8.7B Cerevel deal and an October five-strength oral tablet launch.
Richard Jaenisch weighs how FDA's new NAM rule could reshape preclinical testing and what CMC teams should do now, on Manufacturing Intelligence.
In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor, PhD, AbbVie, and Swita Singh, PhD, Bristol Myers Squibb, discuss the implementation of risk-based approaches for CMC.
Merck licenses SciBrunch's preclinical KRAS G12D inhibitor for $2.13B, raising tech transfer and scale-up questions for oral cancer drug development.
Ronald Piervincenzi, USP, urges drugmakers and purchasers to act on supply chain resilience to curb drug shortages and shape better policy.
Content on PharmTech.com this week ranged from fundamentals on the use of digital pathology in drug development, discussions on the use of AI in pharma, and regulatory actions impacting the industry.